Immunomedics pursues breast imaging

Article

Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, last month submitted to the European Medicines Evaluation Agency (EMEA) a regulatory application for use of its lead product, CEA-Scan, in breast imaging applications. The company believes its

Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, last month submitted to the European Medicines Evaluation Agency (EMEA) a regulatory application for use of its lead product, CEA-Scan, in breast imaging applications. The company believes its clinical trials have demonstrated that the monoclonal antibody-based agent correctly identifies cancer in 82% of the women studied, and in 91%, cancer was correctly ruled out. CEA-Scan is already being sold in the U.S. and Europe for the detection of colorectal cancer.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.